Global healthcare is currently experiencing a substantial shift in the way it operates and caters to patient needs, driven by advancements in science and...
Pfizer's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush...
Sun Pharmaceutical Industries Limited, announced that it has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic Mesalamine...